A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Conditions

Kidney

Phase II

What is the purpose of this trial?

The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab in combination with ipilimumab in treating patients/subjects with advanced renal cell carcinoma.

  • Trial with
    Bristol-Myers Squibb Research and Development
  • Start Date
    08/27/2017
  • End Date
    01/16/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Neta Shanwetter Levit

  • Last Updated
    07/02/2019
  • Study HIC
    #2000020529